PTC299

DRUG5 trials

Sponsors

PTC Therapeutics

Conditions

AMLAdvanced CancerCOVID-19CoronavirusLeukemia, Myeloid, AcuteMetastatic Breast CancerNeurofibromatosis 2Pneumonia

Phase 1

PTC299 and Hormonal Agent for Treatment of Metastatic Breast Cancer

CompletedNCT00508586

PTC TherapeuticsMetastatic Breast Cancer

Start: 2007-11-30End: 2012-03-31Updated: 2016-03-03

PTC299 for Treatment of Advanced Cancer

TerminatedNCT00704821

PTC TherapeuticsAdvanced Cancer

Start: 2008-07-03End: 2012-02-24Updated: 2019-05-10

Study of PTC299 (Emvododstat) in Relapsed/Refractory Acute Leukemias

TerminatedNCT03761069

PTC TherapeuticsAML, Leukemia, Myeloid, Acute

Start: 2018-10-29End: 2021-12-28Updated: 2022-02-02

Phase 2

PTC299 for Treatment of Neurofibromatosis Type 2

TerminatedNCT00911248

PTC TherapeuticsNeurofibromatosis 2

Start: 2009-07-31End: 2012-03-31Updated: 2019-04-12

A Study to Evaluate Efficacy and Safety of PTC299 (Emvododstat) in Hospitalized Participants With Coronavirus (COVID-19)

TerminatedNCT04439071

PTC TherapeuticsCoronavirus, COVID-19, Pneumonia

Start: 2020-07-09End: 2022-07-20Updated: 2023-06-26